tirzepatide surpass trials SURPASS-5: lowers HbA1c in adults with type 2 diabetes on insulin glargine Cardiovascular outcomes of semaglutide and

Preliminary data indicates typical side effects associated with GLP-1 medications, such as nausea, diarrhea, constipation, and occasional increased heart rates during the initial weeks of treatment

TRIUMPH-4: A mean body-weight reduction of approximately 28.7% at 68 weeks on the 12 mg dose

In a meta-analysis that included 15 RCTs involving a total of 2,330 women, the results also indicated that NAC may have a certain efficacy as an adjunct therapy for infertility related to PCOS and unexplained infertility, particularly in women with high BMI, insulin resistance, and oxidative stress [56]

Drug-Metabolizing Enzyme- and Transporter- Mediated DDIs of GLP-1 RAs and a Dual GLP-1/GIP RA To date, no clinically relevant drug-metabolizing enzyme- or transporter-mediated DDIs involving GLP-1 RAs or a dual GLP-1/GIP RA have been reported (Table 3)

The Bottom Line: Dont just chase high GDF15 levels